(Q43667970)

25 November 2017

title

Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing (English)

1 reference

25 November 2017

3

Jones RN

1 reference

25 November 2017

Jamjian C

1

1 reference

25 November 2017

Barrett MS

series ordinal

2

1 reference

25 November 2017

publication date

1 April 1997

1 reference

Diagnostic Microbiology and Infectious Disease

25 November 2017

published in

1 reference

25 November 2017

volume

27

1 reference

25 November 2017

issue

4

1 reference

25 November 2017

page(s)

129-138

1 reference

RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

RP 59500: a proposed mechanism for its bactericidal activity

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

The in-vitro activity of RP 59500 against gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and Enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

Medium and supplement effects on the antimicrobial activity of quinupristin/dalfopristin tested by agar dilution and Etest methods

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

RP 59500 prophylaxis of experimental endocarditis due to erythromycin-susceptible and -resistant isogenic pairs of viridans group streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

Comparative in-vitro activity of RP 59500

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900031-X

7 January 2021

10.1016/S0732-8893(97)00031-X

Identifiers

DOI

1 reference

25 November 2017

1 reference